Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,424 across all filing types
Latest filing 2024-11-29 Declaration of Voting R…
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
Postal Ballot Scrutinizer Report
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an official notice from SeQuent Scientific Limited to the stock exchanges detailing the voting results of a postal ballot (remote e-voting) under Regulation 44 of SEBI Listing Regulations, accompanied by the Scrutinizer’s Report. It provides the outcome of shareholder votes on a special resolution. This aligns precisely with “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2024-11-29 English
General Updates
Share Issue/Capital Change Classification · 100% confidence The document is an official communication from Sequent Scientific Limited to stock exchanges (BSE and NSE) regarding the allotment of equity shares under the company's Employee Stock Option Plan (ESOP 2020). It details the number of shares allotted, exercise price, increase in paid-up capital, and compliance with SEBI regulations. The document is a formal announcement of a share allotment event related to employee stock options, which directly affects the company's capital structure. It is not a full financial report, earnings release, or management discussion, but rather a specific update on share issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely a report publication announcement or a regulatory filing fallback.
2024-11-25 English
Allotment of ESOP
Share Issue/Capital Change Classification · 100% confidence The document is an official communication from Sequent Scientific Limited to stock exchanges (BSE and NSE) regarding the allotment of equity shares under the company's Employee Stock Option Plan (ESOP) 2020. It details the number of shares allotted, exercise price, increase in paid-up capital, and compliance with SEBI regulations. The document includes a disclosure annexure pursuant to SEBI regulations on share-based employee benefits. This is a clear announcement of a share allotment event related to employee stock options, which affects the company's capital structure. It is not a full financial report, earnings release, or management discussion. It is not a proxy, AGM material, or voting result. It is a capital change announcement specifically about share allotment under ESOP. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is not a mere announcement of a report but a substantive disclosure of a capital change event.
2024-11-25 English
Earning Call Transcript: Q2 FY 25
Call Transcript Classification · 100% confidence The document is an extensive transcript of an earnings conference call for Sequent Scientific Limited for the quarter and half year ended September 30, 2024. It includes detailed financial performance data, management commentary, and discussion of strategic developments such as a merger. The text explicitly mentions it is an "Earnings Call Transcript" and contains the full dialogue and financial highlights typically found in such transcripts. It is not merely an announcement or a brief summary but a full transcript of the call. Therefore, the document fits the category of a Call Transcript (CT).
2024-11-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is an extensive transcript of an earnings conference call for Sequent Scientific Limited for the quarter and half year ended September 30, 2024. It includes detailed financial performance data, management commentary, and discussion of strategic developments such as a merger. The text explicitly mentions it is an "Earnings Call Transcript" and contains the full dialogue and financial highlights typically found in such transcripts. It is not merely an announcement or a brief summary but a full transcript of the call. Therefore, the document fits the category of a Call Transcript (CT).
2024-11-22 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. It details the acquisition of incremental stakes in two subsidiaries, N-VET AB and Alivira Italia SRL, making them wholly owned subsidiaries. The content includes specifics about the acquisition, such as percentage acquired, consideration, background of the entities, and regulatory compliance. There is no financial report or earnings data presented; rather, it is a regulatory announcement about shareholding consolidation and acquisition activities. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions that affect ownership structure.
2024-11-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.